<DOC>
	<DOCNO>NCT01368562</DOCNO>
	<brief_summary>This open label compassionate use study subcutaneously administer MNTX subject advance medical illness opioid-induced constipation . Eligible subject initially receive single dose MNTX deliver SC . Subsequent dosing could adjust upward achieve desire clinical response lower alleviate drug relate adverse event ( AEs ) .</brief_summary>
	<brief_title>Compassionate Use Study Methylnaltrexone</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Methylnaltrexone</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>1 . Advanced medical illness ( i.e . terminal illness , incurable cancer end stage AIDS ) life expectancy one six month 2 . On opioid regimen control pain/discomfort least seven day 3 . Has opioidinduced constipation 4 . On laxative regimen ( e.g . stool softener SENNA equivalent ) least 3 day prior treatment . 1 . Patients know hypersensitivity methylnaltrexone , naltrexone naloxone 2 . Patients constipated disease process suggestive gastrointestinal obstruction , impaction diagnose current abdominal pathologic process may represent nonopioid cause bowel dysfunction 3 . Patients constipate active , clinically significant diverticulitis 4 . Patients treat opioids diarrhea , dyspnea , cough , pulmonary edema , congestive heart failure 5 . Individuals know drug addiction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>